Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
about
Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive reviewMarkers of resistance to anti-EGFR therapy in colorectal cancerA Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal CancerNew findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?Personalized treatment for advanced colorectal cancer: KRAS and beyondCancer concepts and principles: primer for the interventional oncologist-part IICetuximab Reconstitutes Pro-Inflammatory Cytokine Secretions and Tumor-Infiltrating Capabilities of sMICA-Inhibited NK Cells in HNSCC Tumor Spheroids.EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis.Standard chemotherapy with cetuximab for treatment of colorectal cancerA let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapyCetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signaturePCR-based assays versus direct sequencing for evaluating the effect of KRAS status on anti-EGFR treatment response in colorectal cancer patients: a systematic review and meta-analysisWhere now for anti-EGF receptor therapies in colorectal cancer?Systematic review on infusion reactions associated with chemotherapies and monoclonal antibodies for metastatic colorectal cancer.Protein kinase inhibitors in metastatic colorectal cancer. Let's pick patients, tumors, and kinase inhibitors to piece the puzzle together!Potential value of PTEN in predicting cetuximab response in colorectal cancer: an exploratory study.Targeting colorectal cancer with anti-epidermal growth factor receptor antibodies: focus on panitumumab.Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trialAdverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancerEfficacy of the monoclonal antibody EGFR inhibitors for the treatment of metastatic colorectal cancer.Cetuximab as second-line therapy in patients with metastatic esophageal adenocarcinoma: a phase II Southwest Oncology Group Study (S0415)Understanding resistance to EGFR inhibitors-impact on future treatment strategiesA let-7 microRNA-binding site polymorphism in KRAS predicts improved outcome in patients with metastatic colorectal cancer treated with salvage cetuximab/panitumumab monotherapy.Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer.Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patientsEpidermal growth factor receptor inhibitors in colorectal cancer treatment: what's new?Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancerCetuximab in the treatment of head and neck cancer: preliminary results outside clinical trialsAnti-IGF-1R monoclonal antibody inhibits the carcinogenicity activity of acquired trastuzumab-resistant SKOV3Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotypingCT versus FDG-PET/CT response evaluation in patients with metastatic colorectal cancer treated with irinotecan and cetuximab.Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy.Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities.Preliminary investigation of intraperitoneal raltitrexed in patients with gastric cancerA review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy.EGFR expression is associated with decreased benefit from trastuzumab in the NCCTG N9831 (Alliance) trialDistinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy.[(18)F]-FLT PET to predict early response to neoadjuvant therapy in KRAS wild-type rectal cancer: a pilot study.Therapeutic antibodies against cancer.
P2860
Q21198850-5E094029-1B49-44C9-B5B3-60EB6FB0FFEEQ24598640-1673AACC-54B5-4E4C-92A6-182619774554Q26775711-2F52B2F8-EABC-44B8-9610-894059E9F641Q26796348-6107EB9C-0D51-4358-AE0B-2C7E6CC18AA9Q26822817-18C638B5-04A2-405E-8006-4C3178772D3BQ27010961-CC1FC7C8-1444-48EE-A8C6-D812EE0F416EQ27329648-25670B11-1053-46CC-992B-EEBB7D002193Q27852970-60859961-91C4-4F19-AD32-D5B92E8DCDBCQ28088693-E1B2D3FF-7C29-45A8-88B6-96713B3A3D1BQ28287088-F1F89B04-0321-4682-B6E1-2EEC1B4FCA5BQ28468648-52D4B0F4-F01E-4392-A6FB-63A3D4A63F26Q28543278-9B0E5880-E0C1-4C75-9C8A-4C8E416C2A34Q31038305-4D183BC1-FF9B-4B80-9D1C-3B7D12203155Q31048123-0295A997-F382-48B4-B304-1407C48E2A82Q33356339-80B9DAB4-78A2-470E-B8D3-A05F3737114AQ33359798-353CF740-2A99-4B49-880E-F6CB3DE92121Q33916016-231C3F2C-AE8C-4A15-B514-867DC5C116FEQ33960370-0AB639DB-3F7F-4106-B790-B83BFEFC6EB2Q33983656-F9E558AE-A178-4179-82EA-2925F80107D3Q33983663-D3B29558-47EA-4061-B509-AA35A867577EQ34084724-128B0697-4A9B-4525-B657-D175869D0132Q34088424-63306E9A-B474-4C55-8C57-EF8FD9302436Q34138308-787748F2-0A1F-4B6D-BE44-3C7250B833A5Q34239801-6ABF815F-0D61-4427-AE5A-E4F2F23E709DQ34316522-E2DDB37A-F1E0-4F7F-8867-D627CB9983DBQ34382797-83DE957F-B501-40C6-A6CC-A1CDC3D75911Q34406526-6E36A3F3-FB6E-4356-80AE-B4813AEC2C16Q34417953-C5A9860B-6A3E-44B5-B734-7CCC63A32FDAQ34659512-84B31AA9-0E8E-4AC1-9DE2-3400CAC2E775Q34760933-3F4B4614-06D9-48A0-A770-A4607D0B8267Q34998534-19C07982-4F0F-402E-ABB8-57E4BFC166E5Q35013457-ECAFA4B8-0298-40A4-9F24-EE1F32AEC99CQ35083960-E86BB176-06C4-4C5C-964E-219E04745EFDQ35414744-7823981A-9DDF-48AE-91FC-EC61726E0B85Q35584153-E5ADA603-8F80-4391-AE66-17CA62CB69A2Q35584416-C15D37EE-1D15-4CB6-A17D-45FA47955CECQ35678436-1138F190-9FFB-4CEF-8CDB-B8165ECD44C8Q35773077-6B88CDFB-1AA1-47DC-BC26-AF5524A4C403Q35855226-A091329C-742E-4B62-86DF-BB76CB090C43Q35908498-570DF348-34B5-4995-B542-C209FF1C575A
P2860
Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Multicenter phase II and trans ...... platin, and fluoropyrimidines.
@ast
Multicenter phase II and trans ...... platin, and fluoropyrimidines.
@en
type
label
Multicenter phase II and trans ...... platin, and fluoropyrimidines.
@ast
Multicenter phase II and trans ...... platin, and fluoropyrimidines.
@en
prefLabel
Multicenter phase II and trans ...... platin, and fluoropyrimidines.
@ast
Multicenter phase II and trans ...... platin, and fluoropyrimidines.
@en
P2093
P356
P1476
Multicenter phase II and trans ...... platin, and fluoropyrimidines.
@en
P2093
Allen L Cohn
Andrew W Pippas
Barry Mirtsching
David J Mauro
Eric K Rowinsky
Nozar Azarnia
Philip Gold
Philip Stella
Robert J Mayer
Shirin Khambata-Ford
P304
P356
10.1200/JCO.2006.06.7595
P407
P577
2006-10-01T00:00:00Z